A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 17, 2010

Primary Completion Date

February 28, 2014

Study Completion Date

January 4, 2017

Conditions

Advanced Solid TumorsAdenocarcinoma of the Prostate

Interventions

DRUG

Alisertib

Alisertib ECT

DRUG

Docetaxel

Docetaxel IV infusion

Trial Locations (4)

Indianapolis

Portland

San Antonio

Seattle